Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-05-05-Speech-3-605"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-05-05"^^xsd:date2
dcterms:Is Part Of	lp_eu:Commission communication on Action against Cancer: European Partnership (debate)2
dcterms:Language	"da"^^xsd:language2
lpv:document identification number	"en.20100505.79.3-605"2
lpv:hasSubsequent	lp_eu:2010-05-05-Speech-3-6062
lpv:speaker	lp:Anna Rosbach2
lpv:spokenAs	substitute; CONT (2009-10-06--2011-03-07)3 vice-chair; Delegation for relations with the Korean Peninsula (2009-09-17--2014-06-30)3 substitute; Delegation for relations with Canada (2009-09-16--2011-03-07)3 substitute; Delegation for relations with Iran (2009-09-16--2011-03-07)3 substitute; Delegation for relations with India (2009-09-22--2011-03-07)3 member; ENVI (2009-07-16--2012-01-18)3 substitute; Delegation for relations with the People's Republic of China (2009-09-22--2011-03-07)3 unknown; Dansk Folkeparti (2009-07-14--2011-03-07)3 member; EFD (2009-07-14--2011-03-07)3 substitute; TRAN (2009-07-16--2011-03-07)3
lpv:translated text	"Mr President, cancer is a widespread disease that, thanks to some intensive research, we are starting to know a great deal about. We now know that a person can be genetically disposed to developing cancer and that at least one enzyme is involved in triggering the disease. Stress, lifestyle, chemicals and viruses can also cause cancer. This year, almost two million European citizens are expected to die of this disease. Thus, cancer does not stop at national borders. I am therefore pleased that the Commission has taken the initiative to draw up an ambitious plan for action against cancer at European level. I have two questions. Where does the Commission stand with regard to research? Can the financial resources that have been allocated ensure effective research and what level of priority is it being given? The Commission points out that the screening volume is low in relation to the Council’s recommendation. Therefore my second question is how will the ambitious target be converted into real patients in our countries? Can we realistically double the effectiveness of our screening throughout Europe?"@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph